



## Sarupria Somani & Associates Chartered Accountants

Partner : CA Miral Bipinbhai Mehta  
B.Com, FCA

314, 3rd Floor, Imperial Arc,  
Opp. Shamaldas College Gate,  
Waghawadi Road, Bhavnagar.  
Tel.: 0278-2564366  
Mobile : 9909366366  
Email : somanibvn@gmail.com

Limited Review Report on standalone un-audited Quarterly financial results for the quarter and half year ended 30<sup>th</sup> September, 2024 of Par Drugs and Chemicals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To,  
The Board of Directors  
Par Drugs and Chemicals Limited

We have reviewed the accompanying statement of unaudited financial results of **Par Drugs and Chemicals Limited** having its registered office at 815, Nilamber Triumph, Gotri Vasna Road, Vadodara, Gujarat-390007 for the quarter and half year ended 30th September, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



### Branches

Udaipur • Ahmedabad • Akola • Mumbai • Delhi • Singruli • Jaipur • Gandhinagar

Our conclusion is not modified in respect of this matter.

SARUPRIA SOMANI & ASSOCIATES

(Firm Regn No. – 010674C)  
CHARTERED ACCOUNTANTS



MIRAL MEHTA (Partner)

M.No.145361

Bhavnagar, 22<sup>nd</sup> October, 2024

UDIN - 24145361BKFOVG6435

PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India  
Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com Website: www.pardrugs.com  
Standalone Audited Financial Results for the Quarter and Half Year Ended 30th September, 2024


Statement Of Profit & Loss

(Rs. in Lakhs)

	Particulars	Quarter Ended			Year to Date		Year Ended
		30/09/2024	30/06/2024	30/09/2023	30/09/2024	30/09/2023	31/03/2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	3,465.69	2,260.56	2,588.73	5,726.25	4,882.21	9,564.04
II	Other income	101.60	7.35	4.91	108.95	6.12	24.23
III	<b>Total Revenue (I + II)</b>	<b>3,567.29</b>	<b>2,267.91</b>	<b>2,593.64</b>	<b>5,835.20</b>	<b>4,888.32</b>	<b>9,588.27</b>
IV	<b>Expenses:</b>						
	Cost of materials consumed	1,083.34	925.44	789.80	2,008.78	1,790.74	3,331.88
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	122.51	-176.83	111.04	-54.33	77.18	47.30
	Employee benefits expense	135.93	126.17	116.77	262.09	229.05	549.89
	Finance costs	2.94	1.99	2.67	4.92	4.23	10.71
	Depreciation and amortization expense	90.82	90.37	84.78	181.19	167.90	343.61
	Other expenses	983.08	962.29	834.87	1,945.36	1,635.77	3,353.23
	<b>Total expenses (IV)</b>	<b>2,418.60</b>	<b>1,929.41</b>	<b>1,939.93</b>	<b>4,348.02</b>	<b>3,904.87</b>	<b>7,636.61</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>1,148.69</b>	<b>338.50</b>	<b>653.71</b>	<b>1,487.19</b>	<b>983.45</b>	<b>1,951.66</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit / (loss) before tax (V - VI)</b>	<b>1,148.69</b>	<b>338.50</b>	<b>653.71</b>	<b>1,487.19</b>	<b>983.45</b>	<b>1,951.66</b>
VIII	<b>Tax expense:</b>						
	(1) Current tax	289.10	85.19	164.53	374.30	247.52	497.56
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	4.00
IX	<b>Profit / (Loss) for the period from continuing operations (VII-VIII)</b>	<b>859.58</b>	<b>253.31</b>	<b>489.18</b>	<b>1,112.89</b>	<b>735.94</b>	<b>1,450.10</b>
X	Profit / (loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	<b>Profit / (loss) from Discontinued operations (after tax) (X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit / (Loss) for the period (IX + XII)</b>	<b>859.58</b>	<b>253.31</b>	<b>489.18</b>	<b>1,112.89</b>	<b>735.94</b>	<b>1,450.10</b>
XIV	<b>Other Comprehensive Income</b>						
	A (i) items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV	<b>Total Comprehensive Income for the period (comprising profit / (loss) and other comprehensive income for the period) (XIII + XIV)</b>	<b>859.58</b>	<b>253.31</b>	<b>489.18</b>	<b>1,112.89</b>	<b>735.94</b>	<b>1,450.10</b>
XVI	Paid up Equity share capital (Face value of Rs. 10 each)	1,230.46	1,230.46	1,230.46	1,230.46	1,230.46	1,230.46
XVII	Reserves & Surplus excluding revaluation reserve	8,445.63	7,586.05	6,629.31	8,445.63	6,629.31	7,332.74
XVIII	Earnings per equity share (for discontinued operation)						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIV	Earnings per equity share (for discontinued & continuing operation) (EPS for 3 and 9 months ended periods are not annualised)						
	(1) Basic	6.99	2.06	3.97	9.04	5.98	11.78
	(2) Diluted	6.99	2.06	3.97	9.04	5.98	11.78


For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Jigneshbhai V. Savani  
Director & CEO  
(DIN - 00198203)



For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Kalgun V. Savani  
(Chairman & Managing Director)  
(DIN - 00198236)



PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com Website: www.pardrugs.com

Standalone Audited Financial Results for the Quarter and Half Year Ended 30th September, 2024

Standalone Balance Sheet as at 30th September, 2024

(Rs. In Lakhs)



Particulars	AS AT 30.09.2024	AS AT 31.03.2024
	Unaudited	Audited
<b>ASSETS</b>		
<b>(1) Non-Current Assets</b>		
(a) Property, Plant and Equipment	4,012.77	4,130.99
(b) Capital Work-in-Progress	0.00	2.50
(c) Investment in Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible Assets	0.00	0.00
(f) Intangible Assets Under Development	0.00	0.00
(g) Biological Assets Other Than Bearer Plant	0.00	0.00
(h) Financial Assets		
(i) Investments	2,586.46	1.19
(ii) Trade receivables	0.00	0.00
(iii) Loans	0.00	0.00
(i) Deferred Tax Assets (net)	0.00	0.00
(j) Other non-current assets	59.89	64.07
<b>Total Non-Current Assets</b>	<b>6,659.13</b>	<b>4,198.76</b>
<b>(2) Current Assets</b>		
(a) Inventories	493.44	417.70
(b) Financial Assets		
(i) Investments	0.00	0.00
(ii) Trade receivables	2,295.57	1,371.42
(iii) Cash and cash equivalents	1,878.24	3,665.39
(iv) Bank balances other than (iii) above	0.00	0.00
(v) Loans	2.90	9.48
(vi) other financial assets	0.00	0.00
(c) Current Tax Assets (Net)	223.13	470.24
(d) Other Current Assets	13.09	28.12
<b>Total Current Assets</b>	<b>4,906.37</b>	<b>5,962.36</b>
<b>TOTAL ASSETS</b>	<b>11,565.49</b>	<b>10,161.11</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	1,230.46	1,230.46
(b) Other Equity	8,445.63	7,332.74
<b>Total Equity</b>	<b>9,676.09</b>	<b>8,563.20</b>
<b>Liabilities</b>		
<b>(1) Non-Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	0.00	0.00
(ia) Lease Liabilities	0.00	0.00
(ii) Trade Payables:-		
(A) Total outstanding dues of micro and small enterprises; and	0.00	0.00
(B) Total outstanding dues of creditors other than micro and small enterprises	0.00	0.00
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	0.00	0.00
(c) Deferred Tax Liabilities (Net)	354.00	354.00
(d) Other Non-Current Liabilities	0.00	0.00
<b>Total Non-Current Liabilities</b>	<b>354.00</b>	<b>354.00</b>
<b>(2) Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	0.00	0.00
(ia) Lease Liabilities	0.00	0.00
(ii) Trade Payables:-		
(A) Total outstanding dues of micro and small enterprises; and	11.65	73.70
(B) Total outstanding dues of creditors other than micro and small enterprises	1,064.24	461.92
(iii) Other financial liabilities	0.00	0.00
(b) Other Current Liabilities	79.87	193.86
(c) Provisions	379.64	514.43
(d) Current Tax Liabilities (Net)	0.00	0.00
<b>Total Current Liabilities</b>	<b>1,535.40</b>	<b>1,243.91</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>11,565.49</b>	<b>10,161.11</b>

For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Jigneshbhai V. Savani  
Director & CEO  
(DIN - 00198203)

For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Falgun V. Savani  
(Chairman & Managing Director)  
(DIN - 00198236)



**PAR DRUGS AND CHEMICALS LIMITED**  
(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India  
Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com Website: www.pardrugs.com  
Standalone Audited Financial Results for the Quarter and Half Year Ended 30th September, 2024  
Statement of Cash Flow


Particulars	(Rs. In Lakhs)	
	Quarter and Half Year Ended	Year Ended
	30.09.2024	31.03.2024
	Unaudited	Audited
<b>A: CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Net profit before tax	1,487.19	1,951.66
<b>Adjusted for:</b>		
Depreciation	181.19	343.61
Income-tax/Prior Year Adjustment	0.00	-10.73
Interest Expense	0.00	0.00
Rent, Interest & Dividend Income	-9.71	-23.21
Profit on Slump Sale of Ankleshar Unit	0.00	0.00
Profit/Loss on sale of assets	0.00	-0.82
	171.47	308.84
<b>Operating Profit/(loss) before working capital changes</b>	<b>1,658.66</b>	<b>2,260.51</b>
<b>Adjustments for changes in working capital</b>		
<u>Adjustments for (increase)/decrease in operating assets</u>		
Loans & Other Non-Current Assets	4.18	8.56
Inventories	-75.74	120.19
Trade Receivables	-924.15	325.47
Loans (Current Assets)	6.58	-1.82
Other Current Assets	15.03	35.03
<u>Adjustments for increase/(decrease) in operating liabilities</u>		
Provisions (Non-Current Liabilities)	0.00	-14.02
Provisions (Current Liabilities)	-11.52	4.81
Other Current Liabilities	-114.00	-4.36
Trade Payables	540.27	-273.52
	-559.34	200.34
<b>Cash Generated from / (used in) Operating activities</b>	<b>1,099.32</b>	<b>2,460.84</b>
Less: Income-Tax paid	-250.45	-435.95
<b>Net Cash generated from / (used in) Operating Activities:</b>	<b>848.87</b>	<b>2,024.89</b>
<b>B: CASH FLOW FROM INVESTING ACTIVITIES:</b>		
Purchase of Fixed Assets	-60.46	-608.03
Sales of Fixed Assets	0.00	1.20
Sale of Investment	-2,585.27	-0.19
Rent, Interest & Dividend Income	9.71	23.21
<b>Net Cash generated from / (used in) Investing Activities:</b>	<b>-2,636.02</b>	<b>-583.81</b>
<b>C: CASH FLOW FROM FINANCING ACTIVITIES:</b>		
Proceeds from Issue of Shares	0.00	0.00
Proceeds from Long Term Borrowings	0.00	0.00
Repayment of Long Term Borrowings	0.00	0.00
Repayment of Short Term Borrowings	0.00	0.00
Dividend Paid	0.00	0.00
Interest paid	0.00	0.00
<b>Net Cash generated from / (used in) Financing Activities:</b>	<b>0.00</b>	<b>0.00</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>	<b>-1,787.15</b>	<b>1,441.09</b>
<b>Opening Balance of Cash and Cash Equivalents</b>	<b>3,665.39</b>	<b>2,224.30</b>
<b>Closing Balance of Cash and Cash Equivalents</b>	<b>1,878.24</b>	<b>3,665.39</b>
<b>Total:</b>	<b>-1,787.15</b>	<b>1,441.09</b>

1. Purchase of fixed assets are stated inclusive of movement of Capital Work in Progress and advance for capital goods between the commencement and end of the year/period and are considered as part of investing activity.

2. The cash flow statement has been prepared under the "indirect method" as set out in the Ind-AS - 7 on Statement of Cash Flow as notified under the Companies (Accounts) Rules, 2014.


For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Jigneshbhai Y. Savani  
Director & CEO  
(DIN - 00198203)



For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Falgun V. Savani  
(Chairman & Managing Director)  
(DIN - 00198236)



# **PAR DRUGS AND CHEMICALS LIMITED**

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com

---

## **NOTES:**

1. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time.
2. The above quarterly and half year to date financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 22<sup>nd</sup> October, 2024.
3. The Statutory auditors of the company have carried out Limited Review of the above quarterly & half yearly financial results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
4. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earning per share (not annualized) in accordance with the Ind AS.
5. Previous Year/Period figures are regrouped / reclassified / rearranged, whenever found necessary to make them comparable with the current period figures.
6. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on "Operating Segments". Accordingly, there are no separate reportable segments as per Ind AS - 108.
7. The Company does not have any subsidiary, associates or joint venture as on 30<sup>th</sup> September, 2024; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.



# **PAR DRUGS AND CHEMICALS LIMITED**

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com

---

8. The above unaudited financial results of the Company are available on the Company's website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company's shares are listed.


9. The Status of investors complaints are as follows:

I. Pending at the beginning of the quarter	-	0
II. Received during the quarter	-	0
III. Disposed-off during the quarter	-	0
IV. Remaining unresolved at the end of the quarter	-	0

For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited




(Mr. Falgun V Savani)  
Chairman & Managing Director)  
DIN - 00198236



For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited



(Mr. Jignesh V. Savani)  
Director & CEO  
DIN - 00198203



Vadodara, 22<sup>nd</sup> October, 2024

To,  
The Board of Directors  
Par Drugs And Chemicals Limited

## CERTIFICATE OF CORRECTNESS OF FINANCIAL RESULTS

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that the financial results of the Company for the quarter and half year ended on September 30<sup>th</sup>, 2024 placed before the meeting do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

For Par Drugs And Chemicals Limited

Date: 22/10/2024


Place: Bhavnagar



(Mr. Jignesh V. Savani)  
Chief Executive Officer



For Par Drugs And Chemicals Limited



(Mr. Chintan P. Chauhan)  
Chief Financial Officer

